Clinical Trials Market (By Phase: Phase 1, Phase 2, Phase 3, and Phase 4; By Study Design: Observational, Interventional, and Expanded Access; By Indication: Oncology, Autoimmune/Inflammation, Diabetes, Central Nervous System, Cardiovascular, Pain Management, and Others) - Global Market Size, Share, Trends Analysis, Segment Forecasts, Regional Outlook 2022 - 2030

The global clinical trials market size was valued at USD 53.87 billion in 2022 and is predicted to hit USD 84.43 bn by 2030 with a registered CAGR of 5.7% during the forecast period 2022 to 2030.

Key Takeaway:

• North America has hed 51.4% of the total market share in 2021.
• Asia Pacific region is growing at the CAGR of 6.8% during the forecast period.
• By indication, the oncology segment has held market share of around 24.5% in 2021.
• The cardiovascular condition segment is growing at a CAGR of 6.3% during the forecast period.
• By sponsor, The pharmaceutical & biopharmaceutical companies has generated largest revenue share of around 71% in 2021.
• By Indication by study design, the interventional trials market for autoimmune/inflammation has captured 83% market share in 2021.
• By study design, the interventional design segment has accounted revenue share of 46% in 2021.
• The expanded access trials segment is projected to register at a CAGR of 6.3% over the forecast period.

Key market Insights:

Clinical trials are a process of clinical research that is governed by a defined protocol which is carefully established to answer a precise patient care query. Clinical trials can be divided into five phases, with every phase playing a distinct purpose within the clinical trial. Every trial adheres to a procedure that designates what types of individuals may participate in the study.

The trials also outline exact plan of procedures, tests, medications, and doses within the trial apart from specifying the span of the study. In recent years, the costs associated with drug development have increased significantly, driving pharma and biotech companies to look for modernizations and smarter ways of conducting business.

One important trend is the outsourcing of clinical research activities by manufacturers. By subcontracting their R&D activities, pharma and biotech companies are reforming the drug development facilities business. The R&D service providers have risen from just a few establishments providing restricted clinical trial facilities to big conglomerates offering a extensive range of facilities like study design, preclinical evaluations, clinical trial management and planning, autonomous safety data audit, bio-statistical analysis and several more. CROs (Contract Research Organizations) started off by providing preclinical & clinical trial services, however they are now venturing into project administration.

Report Scope of the Clinical Trials Market

Crucial factors accountable for market growth are:

• Growing prevalence of chronic disorders
• Increasing number of clinical trials in developing regions
• Growing number of biologics
• Increasing demand for advanced treatments such as personalized medicines

Significant Market Trends:

Phase 3 Segment Reported Foremost Market Stake in 2022

Phase 3 segment recorded the major market stake in the worldwide clinical trials market in 2022 and has garnered revenue share 54.6%. Implementation on a large scale is the major reason for high market share of phase 3. Other factors such as high cost and increasing trend of outsourcing are expected to boost the demand over the estimate period.

The Phase 2 clinical trials are anticipated to advance at the maximum CAGR through the forecast period. The Phase II segment held market share for 19.5% in 2021.

Interventional Study is Projected to Dominate the Study Design Segment of Clinical Trials Market Revenue

The requirement of clinical trials in developing diagnostic tests and vaccines for viral diseases such as the SARS CoV-2 has augmented the demand for clinical trials exponentially. Thus, high incidence of novel viral diseases and ongoing technological improvements in clinical trials are major reason for the high revenue share of interventional study. Interventional study segment is expected to grow at a CAGR of 5.4% from 2022 to 2030. The interventional design segment accounted largest market share 46% in 2022.

Oncology is Projected to Dominate the Indication Segment of Clinical Trials Market Revenue

Constant research on cancer treatment and increasing demand for precision medicine are the major reasons responsible for high market share of oncology. The oncology segment was valued at USD 25 billion by 2030. The oncology segment accounted revenue share 24.5% in 2022 and expected to witness growth at a CAGR of 6.4% over the forecast period 2022 to 2030.

North America is Estimated to be the Largest Market for Clinical Trials

The research study covers key prospects and trends of clinical trials products throughout different regions including Europe, North America, Asia-Pacific, Middle East and Africa, and Latin America. Regionally, clinical trials market is dominated by North America due to high incidence of chronic disorders and presence of latest healthcare infrastructure. The North America clinical trials market was valued USD 24 billion in 2021. North America accounted largest revenue share 51.4% in 2022.

On the other hand, Asia-Pacific is anticipated to witness the rapid growth rate 7.2%, on account of increasing investment by governments in research and growing awareness regarding precision medicine.

Top Players contending in the Market:

• Parexel
• IQVIA
• Charles River Laboratory
• Omnicare
• Kendle
• Chiltern
• Pharmaceutical Product Development, LLC

In order to better recognize the current status of clinical trials, and policies adopted by the foremost countries, Precedence Research predicted the future evolution of the clinical trials market. This research study bids qualitative and quantitative insights on clinical trials market and assessment of market size and growth trend for potential market segments.

Major Market Segments Covered:

By Phase

• Phase 1
• Phase 2
• Phase 3
• Phase 4

By Study Design

• Observational
• Interventional
• Expanded Access

By Indication

• Autoimmune/Inflammation
  • Rheumatoid arthritis
  • Multiple Sclerosis
  • Osteoarthritis
  • Irritable Bowel Syndrome (IBS)
  • Others
• Pain Management
  • Chronic Pain
  • Acute Pain
• Oncology
  • Blood Cancer
  • Solid Tumors
  • Other
• CNS Condition
  • Epilepsy
  • Parkinson's Disease (PD)
  • Huntington's Disease
  • Stroke
  • Traumatic Brain Injury (TBI)
  • Amyotrophic Lateral Sclerosis (ALS)
  • Muscle Regeneration
  • Others
• Diabetes
• Obesity
• Cardiovascular
• Others

By Service Type

• Protocol Designing
• Patient Recruitment
• Laboratory Services
• Site Identification
• Bioanalytical Testing Services
  
  • Cell-based Assays
  • Virology Testing
  • Method Development, Optimization, & Validation
  • Serology, Immunogenicity, & Neutralizing Antibodies
  • Biomarker Testing Services
  • PK/PD (Pharmacokinetics/Pharmacodynamics) Testing Services
  • Other Bioanalytical Testing Services
• Analytical Testing Services
• Clinical Trial Supply & Logistic Services
• Clinical Trial Data Management Services
• Decentralized Clinical Services
• Medical Device Testing Services
• Others

By Sponsor

• Pharmaceutical & Biopharmaceutical Companies
• Medical Device Companies
• Others

By End User

• Hospital
• Laboratories
• Clinics

By Application

• Vaccine
• Cell & Gene Therapy
• Small Molecules
• Other Applications

By Geography

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• United Kingdom
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa (MEA)
• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa